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Abstract
Aims/hypothesis Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity has an independent prognostic association with
major coronary events (MCE). However, no study has investigatedwhether type 2 diabetes status modifies the effect of Lp-PLA2
activity or inhibition on the risk ofMCE.We investigate the interaction between diabetes status and Lp-PLA2 activity with risk of
MCE. Subsequently, we test the resulting hypothesis that diabetes status will play a role in modifying the efficacy of an Lp-PLA2
inhibitor.
Methods A retrospective cohort study design was utilised in two study populations. Discovery analyses were performed in the
Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) cohort based in Scotland, UK. Participants were
categorised by type 2 diabetes control status: poorly controlled (HbA1c ≥ 48mmol/mol or ≥6.5%) and well-controlled (HbA1c <
48 mmol/mol or <6.5%) diabetes (n = 7420). In a secondary analysis of the Stabilization of Atherosclerotic Plaque by Initiation
of Darapladib Therapy (STABILITY) trial of Lp-PLA2 inhibitor (darapladib) efficacy, 15,828 participants were stratified post
hoc by type 2 diabetes diagnosis status (diabetes or no diabetes) at time of recruitment. Lp-PLA2 activity was then divided into
population-specific quartiles.MCEwere determined from linkedmedical records in GoDARTS and trial records in STABILITY.
First, the interaction between diabetes control status and Lp-PLA2 activity on the outcome of MCE was explored in GoDARTS.
The effect was replicated in the placebo arm of STABILITY. The effect of Lp-PLA2 on MCE was then examined in models
stratified by diabetes status. This helped determine participants at higher risk. Finally, the effect of Lp-PLA2 inhibition was
assessed in STABILITY in the higher risk group. Cox proportional hazards models adjusted for confounders were used to assess
associations.
Results In GoDARTS, a significant interaction between increased Lp-PLA2 activity (continuous and quartile divided) and
diabetes control status was observed in the prediction of MCE (p < 0.0001). These effects were replicated in the placebo arm
of STABILITY (p < 0.0001). In GoDARTS, stratified analyses showed that, among individuals with poorly controlled diabetes,
the hazards ofMCE for those with high (Q4) Lp-PLA2 activity was 1.19 compared with individuals with lower (Q1–3) Lp-PLA2
activity (95% CI 1.11, 1.38; p < 0.0001) and 1.35 (95% CI 1.16, 1.57; p < 0.0001) when compared with those with the lowest
activity (Q1). Those in the higher risk group were identified as individuals with the highest Lp-PLA2 activity (Q4) and poorly
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controlled diabetes or diabetes. Based on these observations in untreated populations, we hypothesised that the Lp-PLA2
inhibitor would have more benefit in this higher risk group. In this risk group, Lp-PLA2 inhibitor use was associated with a
33% reduction in MCE compared with placebo (HR 0.67 [95% CI 0.50, 0.90]; p = 0.008). In contrast, Lp-PLA2 inhibitor
showed no efficacy in individuals with low activity, regardless of diabetes status, or among those with no baseline diabetes and
high Lp-PLA2 activity.
Conclusions/interpretation These results support the hypothesis that diabetes status modifies the association between Lp-PLA2
activity and MCE. These results suggest that cardiovascular morbidity and mortality associated with Lp-PLA2 activity is
especially important in patients with type 2 diabetes, particularly those with worse glycaemic control. Further investigation of
the effects of Lp-PLA2 inhibition in diabetes appears warranted.
Data availability STABILITY trial data are available from clinicaltrials.gov repository through the GlaxoSmithKline clinical
study register https://clinicaltrials.gov/ct2/show/NCT00799903. GoDARTS datasets generated during and/or analysed during
the current study are available following request to the GoDARTS Access Managements Group https://godarts.org/scientific-
community/.




GoDARTS Genetics of Diabetes Audit and
Research in Tayside Scotland study
HDL-c HDL-cholesterol
LDL-c LDL-cholesterol
Lp-PLA2 Lipoprotein-associated phospholipase A2
MACE Major adverse cardiovascular events
MCE Major coronary events
SOLID-TIMI 52 Stabilization of Plaque Using
Darapladib-Thrombolysis in
Myocardial Infarction 52
STABILITY Stabilization of Atherosclerotic




The prognostic association of lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) with cardiovascular health and
outcomes, independent of traditional risk factors such as
LDL-cholesterol (LDL-c) was first established by the West
of Scotland Coronary Prevention Study over 19 years ago
[1]. Since then, several studies have replicated this finding,
and Lp-PLA2 was identified as a viable drug target for the
prevention of coronary events [2, 3].
Coronary events are caused by the rupture of atherosclerot-
ic plaques, and a critical step in the formation of atheroscle-
rotic coronary lesions is the accumulation and oxidation of
LDL particles. The vast majority of Lp-PLA2 binds to the
LDL-c particle while circulating in the blood stream, and a
smaller proportion to the HDL-c particle [4]. In vitro studies
have shown that increased LDL-c results in upregulation of
Lp-PLA2, suggesting their regulation in plasma is closely
linked even if their biosynthesis is independent [5].
Therefore, hypothetically, inhibiting the enzyme should have
a cardioprotective effect independent of cholesterol-lowering
therapies.
However, trials with the first Lp-PLA2 inhibitor,
darapladib, were unsuccessful. The Stabilization of
Atherosclerotic Plaque by Initiation of Darapladib Therapy
(STABILITY) trial in individuals with chronic heart disease
did not meet its primary outcome of major adverse cardiovas-
cular events (MACE) [6], though darapladib (SB-480848) did
reduce the risk of the secondary endpoint of major coronary
event (MCE) by 10% (HR 0.90 [95% CI 0.82, 1.00]) [6]. The
difference in these endpoints is the inclusion of ischaemic
strokes in MACE. Observational studies have failed to find
evidence of a relationship between Lp-PLA2 activity and isch-
aemic stroke, summarised in the meta-analysis by Thompson
et al [2]. The Stabilization of Plaque Using Darapladib-
Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI
52) trial found that darapladib did not reduce the risk of
MCE in individuals who had experienced an acute coronary
event [7]. Efforts to progress the drug for clinical use were
therefore discontinued. Nevertheless, Lp-PLA2 remains a
significant and, crucially, independent risk factor for ischae-
mic events, with an additional hypothesised role in the devel-
opment of diabetic retinopathy [8]. However, at present it is
not part of any clinical risk scores for ischaemic events.
Diabetes is a well-established risk factor for CVD.
However, the interaction of type 2 diabetes status and Lp-
PLA2 activity in determining cardiovascular risk has never
been examined in humans. In preclinical data, a reduction in
coronary atherosclerosis with darapladib treatment in a type 2
diabetes porcine model of atherosclerosis was reported [3].
The PLA2G7 gene on chromosome 6 encodes the protein
Lp-PLA2. It has recently been demonstrated that adipose
tissue from individuals with type 2 diabetes has higher levels
of PLA2G7 gene expression compared with that observed in
individuals without diabetes [5]. This suggests a potential
interaction could exist between diabetes status and Lp-PLA2
activity. The inflammatory pathways associated with high Lp-
PLA2 activity could be modified by glycaemic control, which
also has a known relationship with inflammation [9–11]. Thus
Lp-PLA2 and dysglycaemia could synergistically increase the
atherosclerotic plaque instability. This study examines if
diabetes status modifies the relationship between Lp-PLA2
activity and cardiovascular outcomes in a large retrospective
cohort study. The hypothesis generated from the observations
was tested in a post hoc analysis of the STABILITY trial.
Methods
Study design Discovery analyses were performed in the
Genetics of Diabetes Audit and Research in Tayside
Scotland (GoDARTS) cohort. GoDARTS is an observational
cohort study with record-linkedmedical and prescribing histo-
ry for 16,838 participants, who consented to participate in the
study [12]. Ethical approval for the study was provided by the
Tayside Medical Ethics Committee (REF:053/04) and the
study has been carried out in accordance with the
Declaration of Helsinki. Lp-PLA2 activity was measured in
individuals with type 2 diabetes (n = 7420) and the study was
performed in this group. The STABILITY trial was approved
by national regulatory authorities and by local ethics commit-
tees or institutional review boards according to relevant local
regulations. For this study, replication was sought through a
secondary analysis of the STABILITY trial (registration
number: NCT00799903), where 15,828 individuals were
randomised to receive either Lp-PLA2 inhibitor (darapladib)
or placebo. The effect of Lp-PLA2 activity on MCE in the
prognostic/placebo-treated arm of the trial was examined. The
effect of Lp-PLA2 inhibition (darapladib therapy) on MCE
was examined in the full trial population. Retrospective cohort
analyses were performed in both the GoDARTS cohort and in
the STABILITY trial.
The study details three key results. First, we assess the
interaction between Lp-PLA2 activity and diabetes status in
predicting the risk ofMCE. Second, we stratify the association
of Lp-PLA2 with MCE risk by diabetes status. This stratifica-
tion allows us to determine the higher risk group. Third, we
test the efficacy of Lp-PLA2 inhibition in this higher risk
group. The interaction and stratification results are demon-
strated in GoDARTS and the placebo-treated arm of
STABILITY, while the effect of Lp-PLA2 inhibition is
demonstrated in the STABILITY trial population.
Measurement and use of Lp-PLA2 activity There are two
FDA-approved platforms for the detection of Lp-PLA2 in sera
or plasmas; one that measures enzymatic activity and another
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that measures mass of enzyme. The current and improved
enzymatic activity assay (diaDexus PLAC test for Lp-PLA2
Activity; Diazyme, San Francisco, CA, USA) was used for the
first time in the two large cardiovascular outcome trials with
Lp-PLA2 inhibitor, darapladib (e.g. STABILITY) [13].
Measuring enzymatic activity is the preferred platform since
there are recognised issues with the mass assay [14, 15].
Importantly, the same enzymatic activity assay was used for
the analysis of Lp-PLA2 in GoDARTS [8] as was used for
STABILITY. In both studies, Lp-PLA2 activity was
measured from serum samples obtained at the time of recruit-
ment [8].
Consistent with previous investigations of Lp-PLA2 activ-
ity, quartiles of Lp-PLA2 activity were generated for each
study population [1, 8, 13]. Preliminary analyses of interaction
with diabetes status were demonstrated using both linear and
quartile transformed Lp-PLA2 activity.
Diabetes status In GoDARTS, HbA1c levels weremeasured at
recruitment, and Lp-PLA2 activity was measured from
samples collected at recruitment. The WHO criteria for the
diagnosis of type 2 diabetes recommends the use of HbA1c
48 mmol/mol (6.5%) as a threshold for classification of diabe-
tes [16]. We used this threshold in the study population to
categorise the diabetes control status for participants into
well-controlled (HbA1c < 48mmol/mol, n = 1979) and poor-
ly controlled diabetes (HbA1c ≥ 48 mmol/mol, n = 5441). In
STABILITY, diabetes status at recruitment was recorded as
type 2 diabetes requiring pharmacotherapy. HbA1c was
measured only in individuals with diabetes. Since
STABILITY has the added comparison group of drug effect,
interactions and stratifications were performed using diabetes
status at recruitment. This approach allowed us to use the full
trial population and enhance clinical applicability. All analy-
ses in STABILITYwere performed in the intent-to-treat popu-
lation. Therefore, in GoDARTS, diabetes status refers to
diabetes control status and in STABILITY, it refers to the
presence or absence of type 2 diabetes diagnosis.
A flow chart explaining the study populations is provided
in electronic supplementary material (ESM) Fig. 1.
Measurement of outcome: MCE In the STABILITY trial,
MCE included death from CHD, non-fatal myocardial infarc-
tion and urgent coronary revascularisation for myocardial
ischaemia. Crucially, MCE differs from the primary endpoint
because it excludes strokes. MCE in GoDARTS participants
was obtained from a combination of hospital admission
records (non-fatal MCE) and official deaths records using
International Classification of Disease (ICD-10) codes
(http://apps.who.int/classifications/icd10/browse/2016/en).
All codes capturing ischaemic heart disease were used; these
included myocardial infarctions and coronary artery disease,
which contributed the majority of events.
Covariates Potential confounders considered were age, sex,
smoking status, lipid levels (non-HDL-c) and hypertension.
In GoDARTS, the use of hypertension-, lipid- and diabetes-
controlling medications were found to be more informative
predictors of MCE compared with clinical measures.
Therefore, medication use was treated as proxies of
dyslipidaemia, hypertension and diabetes. Information on
medication use was available from community prescribing
records [12]. All models are adjusted for confounders. For
STABILITY, all information was captured at baseline. Since
STABILITY was performed on individuals with stable CHD,
variables in the SMART (Second manifestations of arterial
disease) risk score were used to adjust models. These includ-
ed: age, sex, smoking status, hypertension, high-sensitivity C-
reactive protein (CRP), eGFR, HDL-c and total cholesterol,
and history of cardiovascular events [17]. All cumulative inci-
dence graphs represent the main (unadjusted) effects, while
the adjusted effects are presented in tables and through the
text.
Statistical analysis Individuals with missing data for covari-
ates were minimal, assumed missing at random, and excluded
on a per analysis basis. Differences in these covariates across
the two studies were examined using t tests for continuous
variables and χ2 tests for categorical variables. Survival anal-
yses were undertaken in both studies using Cox proportional
hazards models. Proportional hazards assumptions were tested
for all adjusted models presented using the LIFETEST proce-
dure in SAS 9.4 (SAS Institute, Cary, NC, USA). First inter-
action analyses using continuous Lp-PLA2 activity and diabe-
tes status were undertaken. Subsequently, interactions were
tested between quartile divided Lp-PLA2 and diabetes status
(using the lowest quartile of Lp-PLA2 and well-controlled or
no diabetes as the reference categories). These interactions
demonstrate hazards for those with equivalent LpPLA2 activ-
ity levels across diabetes status, providing an estimate of the
hazards associated with poorly controlled compared with
well-controlled diabetes, or diabetes compared with no diabe-
tes. In STABILITY these interaction analyses were performed
separately for the darapladib and placebo-treated arms of the
trial. Second, the modifying effect of diabetes status on Lp-
PLA2 activity was further explored in models stratified by
diabetes status in GoDARTS and STABILITY. Informed by
these analyses, risk groups were created to determine those at
increased risk of MCE on the basis of their Lp-PLA2 activity
and diabetes status, and to determine who would benefit most
from Lp-PLA2 inhibition. Interaction between Lp-PLA2 inhi-
bition (darapladib vs placebo) and diabetes status was exam-
ined in those with high Lp-PLA2 activity to demonstrate the
effect of Lp-PLA2 inhibition in the hypothesised risk group.
All analyses were performed using SAS 9.4. Plots were
produced using the ‘survminer’ package in R [18]. All





















































































































































































































































































































































































































































































Study population In GoDARTS, 7420 participants with a
recorded diagnosis of type 2 diabetes at baseline had adequate
serum for Lp-PLA2 activity measurement. Of these, 1979
individuals were classified as having well-controlled diabetes
and 5441 had poorly controlled diabetes. The median follow-
up in GoDARTS was 11 years. The total number of MCE in
the cohort was 2230. In STABILITY, 9839 trial participants
did not have diabetes at recruitment, while 5989 had type 2
diabetes (ESM Fig. 1). The median follow-up in STABILITY
was 3.7 years. The total number of MCE in the trial was 1551.
In GoDARTS, Lp-PLA2 activity was divided into quartiles as
follows: quartile 1 (Q1) ≤ 97.2 (median Q1 = 84.4),
Q2 ≤ 117.3 (median Q2 = 107.5), Q3 ≤ 140.7 (median Q3
= 128.2) and Q4 ≤ 377.9 (median Q4 = 160) nmol
min−1 ml−1. In the STABILITY trial, Lp-PLA2 was divided
into quartiles as follows: Q1 ≤ 141.1 (median Q1 = 122.7),
Q2 ≤ 169.3 (median Q2 = 155.6), Q3 ≤ 200.2 (median Q3 =
128.2) and Q4 ≤ 300.1 (median Q4 = 225.5) nmol
min−1 ml−1.
Baseline demography Comparisons were made within each
study, across diabetes status: well-controlled compared with
poorly controlled type 2 diabetes in GoDARTS; and those
with and those without type 2 diabetes in STABILITY
(Table 1). Mean Lp-PLA2 did not differ across the compari-
son groups in GoDARTS (~120 nmol min−1 ml−1), while they
did differ in the STABILITY trial, with the group without
diabetes having higher activity levels (175.5 ± 45.2 vs
167.0 ± 46.9 nmol min−1 ml−1). The mean age differed by
diabetes regulation status in GoDARTS; those with well-
controlled diabetes were older than those with poorly
controlled diabetes (67 years vs 65 years). Average age in
STABILITY was 64 years in both groups. The proportion of
male to female participants did not differ in GoDARTS, while
in STABILITY there were more female participants in the
diabetes group. Higher BMI was associated with poorly
controlled diabetes in GoDARTS and with type 2 diabetes
in the STABILITY trial . LDL-c only differed in
STABILITY, with higher levels observed in the non-
diabetes group. HDL-c levels were higher in the groups with
well-controlled diabetes and in those without diabetes in
GoDARTS and STABILITY, respectively. Triacylglycerol
levels were higher in the groups with poorly controlled diabe-
tes and type 2 diabetes in GoDARTS and STABILITY
respectively. In GoDARTS, a cohort of individuals with type
2 diabetes, only 26.7% had well-controlled diabetes; in the
STABILITY trial, 38% of the participants were in the diabetes
group. An even proportion of participants received the Lp-
PLA2 inhibitor, darapladib, across the two groups in
STABILITY; 38% of those on darapladib and 37.7% on
placebo had type 2 diabetes requiring pharmacotherapy.
Nearly 50% of those with and without diabetes were
randomised to receive darapladib.
Preliminary analysis of effect of Lp-PLA2 effect on MCE
Replication of the established effect between Lp-PLA2 activ-
ity and MCE risk was undertaken using both linear and quar-
tile divided Lp-PLA2 levels in GoDARTS. Both approaches
showed significant associations with MCE. In GoDARTS and
STABILITY, Lp-PLA2 activity per SD increased hazards of
MCE by 1.10 and 1.30 respectively (ESM Tables 1 and 2).
The highest quartile compared with the lowest quartile was
Table 2 Hazards in stratified risk groups based on Lp-PLA2 activity and diabetes status in GoDARTS (Fig. 1)
Variables Full population (n=7419)
HR (95% CI)
Poorly controlled diabetes:
HbA1c≥48 mmol/mol or ≥
6.5% (n=5441) HR (95% CI)
Well-controlled diabetes: HbA1c<48
mmol/mol or <6.5% (n=1979) HR (95% CI)
Well-controlled diabetes + Lp-PLA2 Q1–3 Reference group – Reference group
Well-controlled diabetes + Lp-PLA2 Q4 1.11 (0.92, 1.35) – 1.06 (0.85, 1.33)
Poorly controlled diabetes + Lp-PLA2 Q1–3 1.03 (0.92, 1.16) Reference group –
Poorly controlled diabetes + Lp-PLA2 Q4 1.29 (1.12, 1.47)** 1.19 (1.07, 1.33)** –
Lipid-controlling medication (Yes/No) 1.48 (1.25, 1.76)** 1.66 (1.36, 2.09)** 1.24 (0.93, 1.66)
Diabetes-controlling medication (Yes/No) 1.41 (1.27, 1.57)** 1.55 (1.34, 1.80)** 1.33 (1.13, 1.57)*
Hypertension-controlling medication
(Yes/No)
1.66 (1.46, 1.90)** 1.56 (1.35, 1.81)** 2.20 (1.60, 3.03)**
Age (years) 1.05 (1.04, 1.05)** 1.04 (1.04, 1.05)** 1.06 (1.05, 1.07)**
Smoking status (Yes/No) 1.30 (1.19, 1.42)** 1.36 (1.22, 1.51)** 1.29 (1.07, 1.54)*
Sex (male vs female) 1.29 (1.18, 1.40)** 1.25 (1.13, 1.38)** 1.45 (1.21, 1.72)**
Non-HDL-c (mmol/l) 0.97 (0.91, 1.03) 0.92 (0.89, 1.06) 0.90 (0.81, 1.05)
Proportional hazards assumptions met (p > 0.05)
*p < 0.01; **p < 0.001
Diabetologia
associated with 1.26 (95% CI 1.10, 1.46) and 1.76 (95% CI
1.33, 2.33) higher risk of MCE in GoDARTS and
STABILITY, respectively, in fully adjusted models (ESM



















































































































































Poorly controlled T2D+Lp-PLA2: Q1–3
Poorly controlled T2D+Lp-PLA2: Q4
a
1514 1396 1289 1187 1065 973 881 513 260 44 0
4053 3759 3469 3212 2914 2602 2373 1627 946 129 0
465 431 395 365 340 307 276 198 107 22 0




















































































































Poorly controlled T2D+Lp-PLA2: Q1-3
Poorly controlled T2D+Lp-PLA2: Q4
b
1514 1396 1289 1187 1065 973 881 513 260 44 0
1388 1280 1185 1079 971 852 780 605 348 61 0-
-

















































































































4053 3759 3469 3212 2914 2602 2373 1627 946 129 0
465 431 395 365 340 307 276 198 107 22 0-
-


















Fig. 1 GoDARTS study: demonstration of all risk groups in GoDARTS.
High vs lower Lp-PLA2 activity (Q4 vs Q1–3) and diabetes control
status. (a) The association between diabetes control status and high vs
low Lp-PLA2 activity was significant (z = 3.80, p < 0.0001, HR 1.07
[95% CI 1.04, 1.13]). (b) Stratified effect among participants with poorly
controlled diabetes. Lp-PLA2 activity in the highest quartile (Q4)
compared with activity in Q1–3 was associated with 1.19 times the
hazards of MCE (95% CI 1.07, 1.33) p < 0.001. (c) Stratified effect
among participants with well-controlled diabetes, no significant differ-
ence in hazards of MCE for those with Lp-PLA2 activity in the highest
quartile compared with lower quartiles (HR 1.04 [95% CI 0.86, 1.27]) p
= 0.69. Full model in Table 2. T2D, type 2 diabetes
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Interaction between Lp-PLA2 activity and diabetes status on
risk of MCE in GoDARTS and STABILITYThere was a significant
interaction between linear Lp-PLA2 activity and diabetes
control status in predicting MCE in GoDARTS and the
placebo-treated arm of the STABILITY trial (see ESM
Tables 5 and 6). Similarly, models demonstrating the interac-
tion between quartiles of Lp-PLA2 activity and diabetes
control were consistently significant in both GoDARTS and
STABILITY (pinteraction < 0.005) (see ESM Tables 7 and 8).
The interaction between Lp-PLA2 quartiles and diabetes
status in the darapladib-treated arm was not significant
(ESM Table 9). Further analyses were performed using quar-
tiles of Lp-PLA2 activity.
Stratification of association between Lp-PLA2 and MCE by
diabetes status The effect of successive quartiles of Lp-
PLA2 activity on the risk of MCE was compared across the
stratifying feature, diabetes status in the two study populations
(ESM Tables 10 and 11). In GoDARTS, among those with
poorly controlled diabetes, Lp-PLA2 activity in the highest
quartile (Q4) compared with the lowest quartile (Q1) was
associated with 1.35 higher hazards of MCE (95% CI 1.16,
1.57). By comparison, among those with well-controlled
diabetes Q4 vs Q1 did not significantly increase hazards of
MCE (HR 1.10 [95% CI 0.80, 1.40]; ESM Table 10 and ESM
Fig. 3). In STABILITY, among participants with diabetes,
activity in Q4 vs Q1 was associated with 2.50 times the
hazards of MCE (95% CI 1.70, 3.68) (ESM Table 11; ESM
Fig. 4). Whereas, among participants without diabetes, Q4 vs
Q1 showed a more modest and non-significant increased risk
of MCE (1.27 [95% CI 0.97, 1.96]).
Creating risk groups: Lp-PLA2 Q4 vs Q1–3 and diabetes status
in GoDARTS The stratified effects demonstrate that the effect
of Lp-PLA2 activity is driven by diabetes status and Lp-PLA2
activity in the highest quartile (Q4), therefore activity in the
lower three quartiles (Q1–3) were combined. This helps
reduce the number of comparison groups, prevents inflation
of results and simplifies the analysis. In GoDARTS, the higher
risk group were participants with poorly controlled diabetes
and Lp-PLA2 activity in Q4, while the lower risk group were
participants with well-controlled diabetes and LpPLA2 activ-
ity in Q1–Q3. The higher risk group had increased hazards of
MCE compared with those with poorly controlled diabetes
and Lp-PLA2 activity in Q1–3 (HR 1.19 [95% CI 1.07,
1.33; p < 0.001]) and HR 1.29 (95% CI 1.12, 1.47) p <
0.001, compared with those in the lower risk group (Fig. 1;
Table 2). Analyses demonstrated that, for those with well-
controlled diabetes, there was no risk associated with high
Lp-PLA2 activity. Models were adjusted for sex, age,
smoking status, use of lipid-, diabetes- and hypertension-
controlling medication.














Overall effect 286/2876 (9.9) 259/2930 (8.8) 0.89 (0.75, 1.05) 0.15d – –
Lp-PLA2 Q1 64/859 (7.5) 71/879 (8.1) 1.04 (0.74, 1.46) 0.82 0.004b 0.90c
Lp-PLA2 Q2 60/754 (8.0) 62/740 (8.4) 1.04 (0.73, 1.48) 0.84
Lp-PLA2 Q3 60/626 (9.6) 53/666 (8.0) 0.86 (0.59, 1.25) 0.43
Lp-PLA2 Q4 102/637 (16) 73/645 (11.3) 0.67 (0.50, 0.90) 0.008d
No diabetes
Overall effect 319/4791 (6.7) 301/4801 (6.3) 0.94 (0.80, 1.10) 0.41
Lp-PLA2 Q1 60/1056 (5.7) 52/1058 (4.9) 0.88 (0.61, 1.28) 0.50
Lp-PLA2 Q2 72/1172 (6.1) 72/1192 (6.0) 1.02 (0.74, 1.42) 0.90
Lp-PLA2 Q3 79/1280 (6.2) 72/1277 (5.6) 0.87 (0.63, 1.20) 0.40
Lp-PLA2 Q4 108/1283 (8.4) 105/1274 (8.2) 0.96 (0.74, 1.26) 0.78
Event rate in arm/full trial population 605/7667 (7.9) 560/7731 (7.2) 0.90 (0.81, 1.01) 0.08d
Models adjusted for age, sex, smoking status (ever vs never smoker), hypertension status, HDL-c, total cholesterol, CRP, eGFR and history of
cerebrovascular disease
a Interactions have been tested between Lp-PLA2 quartiles and diabetes status in those who were placebo-treated and in those who were darapladib-
treated
b Full adjusted model in ESM Table 8
c Full adjusted model in ESM Table 9
d Full adjusted models in ESM Table 13
Proportional hazards assumptions met (p > 0.05)
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Effect of Lp-PLA2 inhibitor (darapladib) on risk of MCE in
STABILITY taking into consideration baseline Lp-PLA2 activity
and diabetes status Based on the stratified observational
analysis above, we hypothesised that in the STABILITY
trial among those with high Lp-PLA2 activity (Q4, n =
3835), participants with diabetes would benefit more from
treatment with an Lp-PLA2 inhibitor than those without
diabetes (Fig. 2). Interaction between Lp-PLA2 inhibition
and diabetes status was tested and found to be non-
significant (Wald χ2 = 2.85, df = 1, p = 0.09).
However, Lp-PLA2 inhibition reduced risk of MCE in
those with diabetes (HR 0.67 [0.50, 0.90]; p = 0.008)
compared with those without diabetes (full model in
ESM Table 12 and stratum-wise effect in Table 3).
In the full trial population, event rate in each quartile by
treatment and diabetes status are presented in Table 3, which
shows 16% of those with type 2 diabetes in Q4 receiving
placebo had MCE, compared with 11.3% of those receiving
darapladib. The table shows that the drug treatment effect was
not apparent in those without diabetes or in any of the lower
quartiles of Lp-PLA2 activity regardless of diabetes status
(Table 3). Models were adjusted for age, sex, hypertension
status, smoking status, HDL-c, total cholesterol, CRP and
eGFR. Full models for other key populations, i.e. full trial
population, type 2 diabetes population, type 2 diabetes with
high Lp-PLA2 activity, and those with no diabetes with lower
Lp-PLA2, are presented in ESM Table 13 along with survival
plots (ESM Fig. 5).
Discussion
We provide evidence that diabetes status modifies the effect of
Lp-PLA2 activity on MCE. We were able to confirm this
enhanced prognostic effect among individuals with type 2
diabetes with high Lp-PLA2 activity in the placebo arm of
the STABILITY trial. We also demonstrate that the same
subgroup exhibited an enhanced response to Lp-PLA2 inhib-
itor, darapladib. While the interaction p value for darapladib
treatment by diabetes status in patients with high Lp-PLA2
(≤300.1 nmol min−1 ml−1) was not significant, a clear and
consistent pattern is observed within and between the two
study populations where an interaction was seen between
enzyme activity and diabetes status (whether defined by type
2 diabetes status or HbA1c threshold). In the higher risk group,
pharmacological inhibition of Lp-PLA2 activity conferred a
33% reduction in the risk of MCE. Our results identify an at-
risk group most likely to benefit from the inhibition of Lp-
PLA2 activity.
The heightened effect observed in a hyperglycaemic envi-
ronment is consistent with the established paradigm that both
type 1 and 2 diabetes are significant and independent risk
factors for coronary artery disease. It is understood that
hyperglycaemia induces alterations in vascular tissue that
accelerate atherosclerosis [19, 20]. One of the hypothesised
pathways suggests that glycation confers increased suscepti-
bility of LDL-c to oxidative modification [9, 10], a process
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 Number at risk
Fig. 2 STABILITY trial: effect of
Lp-PLA2 inhibitor (darapladib)
therapy in the highest quartile of
Lp-PLA2 activity (Q4) by
diabetes status. T2D = 0 if no
type 2 diabetes (T2D), T2D = 1 if
type 2 diabetes; Tx, treatment. HR
for Lp-PLA2 inhibition in those
with type 2 diabetes 0.67 (95% CI
0.50, 0.90) p = 0.008. HR for Lp-
PLA2 inhibition in those with no
type 2 diabetes 0.96 (95% CI
0.74, 1.26) p = 0.78
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atherosclerotic plaques. The danger with these plaques is not
related to their size but primarily to their instability or tenden-
cy to rupture [3, 21]. This is also evidenced in our analyses,
where poor glycaemic control is associated with a higher
event rate. In STABILITY, all participants had CHD, while
GoDARTS was a more general population. We observed that
the effect of higher enzymatic activity in the context of type 2
diabetes was more pronounced in STABILITY than in
GoDARTS, suggesting a biological and clinical risk gradient.
Furthermore, the reported stratifying effect of glycaemic
control also highlights a potential reason for the failure of
Mendelian randomisation studies of Lp-PLA2 activity and
cardiovascular outcomes based on PLA2G7 variants [22, 23].
An in vitro study showed that inhibition of Lp-PLA2
reduced production of oxidised LDL-c by 19.8% [5].
Members of the phospholipase A2 superfamily promote the
formation of oxidised LDL, which in turn is a producer of
proinflammatory mediators. It could be that in the context of
metabolic disease, where the production of proinflammatory
mediators such as lysophosphatidylcholine and oxidised fatty
acids is enhanced, an increase in circulating Lp-PLA2 is even
more damaging.
A limitation of this study is the post hoc nature of the analysis
in selected endpoints. However, this subgroup analysis in
STABILITY was driven by the findings in GoDARTS.
Another limitation is the use of different definitions of diabetes
status. Well-controlled diabetes (the definition used in
GoDARTS) refers to the achievement of target HbA1c levels that
markedly reduce risk of microvascular and macrovascular
complications [24, 25]. Risk of poor outcomes for those with
diabetes who achieve this degree of glycaemic control is reported
to be similar to those without diabetes [26–30]. Using an HbA1c-
based definition in STABILITY would mean limiting our anal-
yses to just the participants with diabetes (ESM Fig. 1). The use
of a surrogate and weaker definition for diabetes status likely
weakens the result leading to an underestimation of the effect.
While marginal efficacy was observed in the original
STABILITY analysis for MCE, this was not the case in the
acute coronary syndrome trial SOLID-TIMI 52 [7]. We
hypothesise this may have been because the drug was admin-
istered too late after the event (10–14 days) or because Lp-
PLA2 may be less relevant in the acute setting. Crucially,
STABILITY and SOLID-TIMI 52 are not comparable due
to their different designs and objectives. Together with
absence of effect in SOLID-TIMI 52 and the difficulties of
performing a prognostic analysis in the acute setting, we chose
to focus on the STABILITY trial. We focused on MCE in
STABILITY as no effect on strokes (included in MACE)
was observed in the trial. Observational studies have consis-
tently reported an association between Lp-PLA2 activity and
risk of CHD, while showing no evidence of greater risk of
ischaemic strokes with increased Lp-PLA2 activity (RR 1.08
[95% CI 0.97, 1.20]) [1, 2, 31]. From a genetic perspective,
analysis of an Lp-PLA2 null variant within the Kadoorie study
also demonstrated no effect on ischaemic stroke [32].
A crucial strength of the reported findings is that the results
were independent of all clinical risk factors based on the
SMART risk score [17]. This implies that Lp-PLA2 activity
is a significant and independent predictor of coronary events
for individuals with type 2 diabetes. Together with the phar-
macological effect of Lp-PLA2 inhibition, these results
suggest there is value in the measurement of enzymatic activ-
ity for individuals with diabetes for risk prediction. It is worth
noting that the effects persisted even though Lp-PLA2 activity
was different in these two study populations, with
STABILITY having higher activity.
The results presented in this manuscript offer the intriguing
possibility of a precision medicine approach, in what is still a
substantial patient population. The frequency of a loss-of-
function variant in the gene PLA2G7, which results in 50%
lower Lp-PLA2 activity, varies significantly by ethnicity [33].
This highlights the value in exploring the comparative risk
reduction through Lp-PLA2 inhibition in different ethnicities.
The development of new cardiovascular therapies over and
above cholesterol-lowering drugs and platelet aggregation
inhibitors has been extremely challenging in recent years.
One factor here is the vast heterogeneity in patients with type
2 diabetes, which has up to this point mainly been countered
with polypharmacy. In the STABILITY trial, patients were on
an average of nine medications throughout the trial. It is possi-
ble that novel therapies may only be successful if the most
appropriate patients can be identified. Unfortunately, in most
instances the most relevant patient population can only be
identified after trials have completed which, given the extend-
ed timelines of cardiovascular outcome trials, will be too late.
One current example of this approach is the DalGene trial,
which is utilising a genetic biomarker to stratify patients
(ClinicalTrials.gov registration no. NCT02525939).
Our results show that individuals most likely to benefit
from inhibition of Lp-PLA2 are those with high activity and
type 2 diabetes. However, while not supported by the trial
data, it is possible that in a diabetic population, those with
intermediate levels of Lp-PLA2 activity may also benefit from
Lp-PLA2 inhibition. However, further appropriately designed
RCTs would be required to determine this. At present, it is not
possible to detangle whether the potential treatment interac-
tion is in fact specific to Lp-PLA2 as it is possible that the
effect relates to the increased absolute risk in participants with
type 2 diabetes. The hypothesis that darapladib would benefit
patients with diabetes and high Lp-PLA2 activity needs to be
tested in a new prospective RCT. A trial designed to analyse
the impact of different thresholds of glycaemic control on the
association between Lp-PLA2 activity, inhibition and risk of
cardiovascular outcomes would be valuable. This would
enable precise delivery of preventative care to those most
likely to benefit from it.
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